No-Fee CE: Myopia Beyond 2025 - Scorecard - MDSpire

No-Fee CE: Myopia Beyond 2025

This course is designed to help readers understand the development of the disease of myopia. The article identifies areas in which clinicians can intervene to slow progression using the latest research evidence from the past year.

  • By

  • CARA FRASCO LAI, OD, MS

  • Nicky Lai, OD, MS

  • March 1, 2026

  • 29 min

Share

Clinical Scorecard: No-Fee CE: Myopia Beyond 2025

At a Glance

CategoryDetail
ConditionMyopia Management
Key MechanismsParental myopia, reduced time outdoors, low hyperopic reserve, axial elongation.
Target PopulationChildren at risk for myopia and those already myopic.
Care SettingOptometry and eyecare practices.

Key Highlights

  • FDA approval of a spectacle lens for myopia control in late 2025.
  • Low hyperopic reserve is the greatest predictive factor for myopic progression.
  • Increased time spent outdoors is associated with reduced risk of myopia onset.
  • A 1-year delay in myopia onset can significantly lower final myopia levels.
  • Emerging research indicates early changes in choroidal thickness may predict treatment efficacy.

Guideline-Based Recommendations

Diagnosis

  • Assess parental myopia and hyperopic reserve.
  • Monitor axial elongation in children.

Management

  • Implement comprehensive myopia management programs.
  • Provide lifestyle recommendations to enhance retinal signaling.

Monitoring & Follow-up

  • Regularly evaluate retinal image quality and axial length.

Risks

  • Children with low hyperopic reserve are at increased risk for developing myopia.

Patient & Prescribing Data

Children, particularly those with parental myopia and low hyperopic reserve.

Use evidence-based optical and/or pharmaceutical treatments to optimize retinal growth regulation.

Clinical Best Practices

  • Encourage increased outdoor time for children.
  • Utilize soft multifocal contact lenses for myopia management.

Related Resources & Content

Original Source(s)

No-Fee CE: Myopia Beyond 2025

  • by CARA FRASCO LAI, OD, MS, Nicky Lai, OD, MS

  • March 1, 2026

Related Content

Evaluating the effect of a new myopia control spectacle lens among children in Israel: 24-month results

CSO Meeting 2026 Highlights Convergence of Innovation and Clinical Practice

More than 300 professionals gathered for three days of innovation, education, and collaboration, highlighting the latest advances in ophthalmic technology and clinical practice

  • May 12, 2026

  • 2 min
Myopia Severity Tied to Pediatric Retinal Pathology

Routine dilated examinations identified peripheral retinal abnormalities across refractive groups, with higher pathology rates among patients with at least 3.00 D of myopia